ClinicalTrials.gg
RecruitingNCT07089186Updated Jul 30, 2025

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections

A Phase 3 interventional study of Meropenem and Pralurbactam and Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam) in Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) and Complicated Intra-abdominal Infection (cIAI), sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing meropenem in Sepsis — 4 open to participants now, 5 under way, 1 of them phase 3. Meropenem · Sepsis.

Planned enrollment
11th of 16
80 · median 190
Started
2025
with 1 other
Phase 3
4 of 16
1 open now
Registered
13th of 16
by date

Among the 16 studies testing meropenem in Sepsis, this one is the 11th largest by planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 3, and was the 13th registered.

Sepsis

2,418 studies on the registry are indexed under Sepsis; 542 are open to participants now.

Browse Sepsis studies →

Open to participants now

4 of the 16 studies testing meropenem in Sepsis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About meropenem

Meropenem: first FDA approval 1996 (MERREM IV), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 318 Sepsis studies recruiting now, 213 (67%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing meropenem in Sepsis, or all of them as a file.
02

Study summary

The study will evaluate the efficacy and safety of Meropenem and Pralurbactam versus Best Available Therapy in the treatment of Carbapenem-Resistant Enterobacteriaceae Infections. Infections evaluated in the study will be hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI), and Bloodstream Infection (BSI).

03

Conditions studied

  • Hospital-acquired Bacterial Pneumonia (HABP)
  • Ventilator-associated Bacterial Pneumonia (VABP)
  • Complicated Intra-abdominal Infection (cIAI)
  • Complicated Urinary Tract Infection (cUTI)
  • Bloodstream Infection (BSI)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized male or female≥18 and ≤80 years of age,
  • Participant must have a diagnosis of an infection (HABP/VABP, cUTI, cIAI, BSI) due to confirmed Carbapenem-Resistant Enterobacteriaceae infection, requiring administration of IV antibacterial therapy
  • Participant who had received appropriate prior empiric antibacterial therapy for a carbapenem-resistant pathogen must meet at least 1 of the following criteria: no or no more than 24h; worsening of objective symptoms or signs after at least 48 hours of antibacterial therapy; no change of objective symptoms or signs after at least 72 hours of antibacterial therapy
  • The estimated survival time is more than 28 days
  • Understand and abide by the research procedures and methods, voluntarily participate in this research, and sign an form

Exclusion criteria

Exclusion Criteria:

  • Participants who need more than 3 systemic antibiotics as part of best available treatment (BAT)
  • Participant is expected to require more than 21 days of treatment
  • Acute Physiology and Chronic Health Evaluation (APACHE) II score >30 using the most recent available data
  • Other medical or psychiatric condition may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Those who participated in other clinical trials within 28 days before randomization and used any test drugs or medical devices
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Meropenem and Pralurbactam

    Meropenem and Pralurbactam (180min infusion)

    Drug: Meropenem and Pralurbactam

  • Active comparator
    Best Available Therapy

    Subjects will receive Best Available Therapy (IV antibiotics)

    Drug: Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)

Interventions

  • DrugMeropenem and Pralurbactam

    Drug pages: Meropenem · Pralurbactam

    3g,q8h,180min infusion,Dose adjustments are available for participants with eGFR(mL/min)

  • DrugBest Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)

    The main therapeutic agents anticipated for use, either in combination or as monotherapy, commonly include colistin, meropenem, tigecycline, amikacin, and ceftazidime-avibactam.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With a Response of Overall Success(clinical response and microbiological response)[Complicated Urinary Tract Infection (cUTI)]

    Time frame: at Test of Cure (TOC) visit (Day 12-23)

  2. Proportion of Participants Who Died Due to Any Cause[Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP) and Bloodstream Infection(BSI) Subjects]

    Time frame: Day 28

  3. Proportion of Participants With a clinical response [Complicated Intra-abdominal Infection (cIAI) Subjects]

    Time frame: at Test of Cure (TOC) visit (Day 10-23

07

Study locations

1 of 1 sites recruiting
  • Huashan Hospital, Fudan Universit
    Shanghai, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 66 phase 3 interventional studies under Sepsis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 65. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2025
First posted
Jul 28, 2025
StartActual
Apr 12, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Apr 2027
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07089186
Responsible party
Sponsor
First posted
Jul 28, 2025
Start date
Apr 12, 2025
Primary completion
Dec 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jul 30, 2025

Study contacts

Haihui Huang, PhD
Contact
Huanghaihui73@aliyun.com
021-52888195

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Meropenem · Pralurbactam

Start the discussion